Get the Stockscreener App
275.03
0.04%
0.12
After Hours:
275.03
Alnylam Pharmaceuticals Inc stock is traded at $275.03, with a volume of 816.58K.
It is up +0.04% in the last 24 hours and up +4.70% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$274.91
Open:
$275.5
24h Volume:
816.58K
Relative Volume:
0.88
Market Cap:
$35.17B
Revenue:
$2.34B
Net Income/Loss:
$-72.94M
P/E Ratio:
-66.43
EPS:
-4.14
Net Cash Flow:
$318.87M
1W Performance:
+1.18%
1M Performance:
+4.70%
6M Performance:
+84.03%
1Y Performance:
+55.30%
1-Day Range:
$272.55
$277.84
1-Week Range:
$267.13
$278.24
52-Week Range:
$141.97
$287.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
New Alnylam HELIOS-B vutrisiran data presented at HFSA - The Pharma Letter
Driehaus Capital Management LLC Makes New $7.90 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
The Manufacturers Life Insurance Company Lowers Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 - StockTitan
(ALNY) Trading Report - Stock Traders Daily
Short Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expands By 18.0% - MarketBeat
Susquehanna Fundamental Investments LLC Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Wall Street SWOT: Alnylam stock poised for growth on promising pipeline - Investing.com Canada
Zacks Research Analysts Increase Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $279.14 - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by APG Asset Management US Inc. - MarketBeat
Deerfield Management Company L.P. Series C Buys Shares of 119,800 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Q1 2026 EPS Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Raised by Analyst - MarketBeat
Alnylam to Webcast TTR Investor Day - StockTitan
Transthyretin Amyloidosis Treatment Market Opportunities - openPR
Primary Hyperoxaluria Treatment Market: 2024 Global Future - openPR
Ensign Peak Advisors Inc Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans - The Business Journals
Tri Locum Partners LP Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
Canada Pension Plan Investment Board Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Skandinaviska Enskilda Banken AB publ - MarketBeat
Alnylam Seeks To End Inventorship Suit Tied To COVID Vax - Law360
Alnylam Pharmaceuticals' (ALNY) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
REGN: 3 Genomics Stocks Transforming Healthcare - StockNews.com
E Fund Management Co. Ltd. Acquires 2,112 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
108 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Ashton Thomas Private Wealth LLC - Defense World
When (ALNY) Moves Investors should Listen - Stock Traders Daily
Dai ichi Life Insurance Company Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Google DeepMind, Isomorphic Labs Predicts Over 200 Million Protein Structures - AIM
TD Cowen maintains Alnylam stock at Buy rating with steady price target - Investing.com India
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Federated Hermes Inc. - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Decline in Short Interest - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Decline in Short Interest - Defense World
Alnylam Stock Soars 65%: Find Out What's Behind the Gains - MSN
Forsta AP Fonden Has $6.12 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Victory Capital Management Inc. Trims Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
National Bank of Canada FI Trims Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Forsta AP Fonden Reduces Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Bullish on This Aggressive Growth Stock - Insider Monkey
Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Bullish on This Aggressive Growth Stock - Yahoo Finance
Daiwa Securities Group Inc. Has $2.74 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
State of New Jersey Common Pension Fund D Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Andra AP fonden Invests $753,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly - The Wall Street Journal
Have you been able to find a good deal on Alnylam Pharmaceuticals Inc’s shares? - US Post News
1,389 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Ballentine Partners LLC - Defense World
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%? - Simply Wall St
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by American Century Companies Inc. - MarketBeat
Principal Financial Group Inc. Sells 5,167 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):